Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

84
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
84
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

64
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
64
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

49
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
49
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

25
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
25
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

51
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
51
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

61
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
61

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteinuria remission and long-term kidney outcome in children with IgA nephropathy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Microscopic hematuria in IgA nephropathy: a biomarker of disease activity.

Clinical kidney journal·2026
Same author

Individualized treatment effects of corticosteroids in IgA nephropathy.

medRxiv : the preprint server for health sciences·2025
Same author

Expected and verified benefits from old and new corticosteroid treatments in IgA nephropathy: from trials in adults to new IPNA-KDIGO guidelines.

Pediatric nephrology (Berlin, Germany)·2025
Same author

Histologic and Clinical Factors Associated with Kidney Outcomes in IgA Vasculitis Nephritis.

Clinical journal of the American Society of Nephrology : CJASN·2024
Same author

IgA vasculitis nephritis in children and adults: one or different entities?

Pediatric nephrology (Berlin, Germany)·2020

Related Experiment Video

Updated: Sep 18, 2025

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

1.9K

Treating IgA Nephropathy: Looking at the Future Without Forgetting the Past.

Rosanna Coppo1

  • 1Fondazione Ricerca Molinette, 10129 Turin, Italy.

Journal of Clinical Medicine
|June 26, 2025
PubMed
Summary

IgA nephropathy (IgAN) treatment is evolving. While corticosteroids show benefits, newer approaches like targeted budesonide and novel drugs offer comparable efficacy with improved safety for kidney protection.

Keywords:
B cellsIgA nephropathycomplementcorticosteroidsendothelintargeted released formulation of budesonidetreatment

More Related Videos

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

1.9K
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

871

Related Experiment Videos

Last Updated: Sep 18, 2025

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

1.9K
Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

1.9K
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

871

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • IgA nephropathy (IgAN) is an inflammatory kidney disease driven by galactose-deficient IgA1 (Gd-IgA1) and subsequent immune complex deposition.
  • Proteinuria is a key marker for IgAN progression, necessitating effective kidney protection strategies.

Purpose of the Study:

  • To review the current treatment landscape for IgA nephropathy (IgAN), focusing on corticosteroids and emerging therapies.
  • To evaluate the efficacy and safety of different treatment modalities in managing IgAN and preventing kidney function decline.

Main Methods:

  • Review of clinical trials and guidelines concerning IgA nephropathy (IgAN) treatments.
  • Analysis of systemic corticosteroids, targeted budesonide, and novel therapeutic agents targeting IgAN pathogenesis.

Main Results:

  • Systemic corticosteroids offer kidney protection but carry significant adverse event risks, leading to guideline revisions.
  • Reduced-dose methylprednisolone with prophylaxis and targeted budesonide show comparable efficacy to full-dose corticosteroids with improved safety profiles.
  • Emerging therapies targeting B cells, complement activation, and the endothelin system demonstrate promising results for IgAN treatment.

Conclusions:

  • The management of IgA nephropathy (IgAN) is shifting towards safer and more targeted therapeutic strategies.
  • Novel drug development holds significant promise for improving long-term kidney outcomes in IgAN patients.